4% ASTRACAINE DENTAL WITH EPINEPHRINE FORTE 1:100,000 (0.01MG/ML) SOLUTION Canada - engelsk - Health Canada

4% astracaine dental with epinephrine forte 1:100,000 (0.01mg/ml) solution

dentsply canada limited - articaine hydrochloride; epinephrine (epinephrine bitartrate) - solution - 40mg; 0.01mg - articaine hydrochloride 40mg; epinephrine (epinephrine bitartrate) 0.01mg - local anesthetics

4% ASTRACAINE DENTAL WITH EPINEPHRINE 1:200,000 (0.005MG/ML) SOLUTION Canada - engelsk - Health Canada

4% astracaine dental with epinephrine 1:200,000 (0.005mg/ml) solution

dentsply canada limited - articaine hydrochloride; epinephrine (epinephrine bitartrate) - solution - 40mg; 0.005mg - articaine hydrochloride 40mg; epinephrine (epinephrine bitartrate) 0.005mg - local anesthetics

Articaine hydrochloride/Epinephrine NewLine Pharma 40 mg/mL + 0.01 mg/mL, solution for injection Irland - engelsk - HPRA (Health Products Regulatory Authority)

articaine hydrochloride/epinephrine newline pharma 40 mg/ml + 0.01 mg/ml, solution for injection

newline pharma, s.l. - articaine hydrochloride; adrenaline tartrate - solution for injection - 40+0.01 milligram(s)/millilitre - articaine, combinations

septocaine- Articaine hydrochloride and epinephrine bitartrate injection, solution USA - engelsk - NLM (National Library of Medicine)

septocaine- articaine hydrochloride and epinephrine bitartrate injection, solution

septodont, inc. - articaine hydrochloride (unii: qs9014q792) (articaine - unii:d3sq406g9x), epinephrine bitartrate (unii: 30q7ki53ak) (epinephrine - unii:ykh834o4bh) - injection, solution - 40 mg in 1 ml - septocaine® is indicated for local, infiltrative, or conductive anesthesia in both simple and complex dental and periodontal procedures. septocaine® is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type, or in patients with known hypersensitivity to sodium metabisulfite.

4% Articadent DENTAL with adrenaline (epinephrine) 1:100,000 articaine hydrochloride and adrenaline (epinephrine) 2.2 mL injection cartridge Australia - engelsk - Department of Health (Therapeutic Goods Administration)

4% articadent dental with adrenaline (epinephrine) 1:100,000 articaine hydrochloride and adrenaline (epinephrine) 2.2 ml injection cartridge

dentsply sirona pty ltd - articaine hydrochloride, quantity: 40 mg/ml; adrenaline (epinephrine) acid tartrate, quantity: 18.2 microgram/ml (equivalent: adrenaline (epinephrine), qty 10 microgram/ml) - injection, solution - excipient ingredients: sodium chloride; sodium metabisulfite; sodium hydroxide; hydrochloric acid; water for injections - 4 percent articadent dental with adrenaline 1:100,000 is indicated for local or regional anaesthesia for both simple and complex dental procedures in adults, adolescents and children 4 years of age and older. 4 percent articadent dental with adrenaline 1:100,000 is indicated only for dental procedures.

ZORCAINE- articaine hydrochloride and epinephrine injection, solution USA - engelsk - NLM (National Library of Medicine)

zorcaine- articaine hydrochloride and epinephrine injection, solution

septodont, inc. - articaine hydrochloride (unii: qs9014q792) (articaine - unii:d3sq406g9x), epinephrine bitartrate (unii: 30q7ki53ak) (epinephrine - unii:ykh834o4bh) - zorcaine®  is indicated for local, infiltrative, or conductive anesthesia in both simple and complex dental procedures in adults and pediatric patients 4 years of age or older. zorcaine is contraindicated in patients who are hypersensitive to products containing sulfites. products containing sulfites may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people [see warnings and precautions (5.5)]. teratogenic effects - pregnancy category c. there are no adequate and well-controlled studies in pregnant women with zorcaine. articaine hydrochloride and epinephrine (1:100,000) has been shown to increase fetal deaths and skeletal variations in rabbits when given in doses approximately 4 times the maximum recommended human dose (mrhd). zorcaine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. in embryo-fetal toxicity studies in rabbits, 80 mg/kg, subcutaneously (approximately 4 times the mrhd based on body surface area) caused fetal death and increased fetal skeletal variations, but these effects may be attributable to severe maternal toxicity, including seizures, observed at this dose. in contrast, no embryo-fetal toxicities were observed when articaine and epinephrine (1:100,000) was administered subcutaneously throughout organogenesis at doses up to 40 mg/kg in rabbits and 80 mg/kg in rats (approximately 2 times the mrhd based on body surface area). in pre- and postnatal developmental studies subcutaneous administration of articaine hydrochloride to pregnant rats throughout gestation and lactation, at a dose of 80 mg/kg (approximately 2 times the mrhd based on body surface area) increased the number of stillbirths and adversely affected passive avoidance, a measure of learning, in pups. this dose also produced severe maternal toxicity in some animals. a dose of 40 mg/kg (approximately equal to the mrhd on a mg/m2 basis) did not produce these effects. a similar study using articaine and epinephrine (1:100,000) rather than articaine hydrochloride alone produced maternal toxicity, but no effects on offspring. it is not known whether zorcaine is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when zorcaine is administered to a nursing woman. when using zorcaine, nursing mothers may choose to pump and discard breast milk for approximately 4 hours (based on plasma half life) following an injection of zorcaine (to minimize infant ingestion) and then resume breastfeeding. safety and effectiveness of zorcaine in pediatric patients below the age of 4 years have not been established. safety of doses greater than 7 mg/kg (0.175 ml/kg) in pediatric patients has not been established. the safety and effectiveness of zorcaine for local, infiltrative, or conductive anesthesia in both simple and complex dental procedures have been established in pediatric patients ages 4 to 16 years old. safety and effectiveness was established in clinical trials with 61 pediatric patients between the ages of 4 and 16 years administered articaine hydrochloride 4% and epinephrine 1:100,000 injections. fifty-one of these patients received doses from 0.76 mg/kg to 5.65 mg/kg (0.9 to 5.1 ml) for simple dental procedures and 10 patients received doses between 0.37 mg/kg and 7.48 mg/kg (0.7 to 3.9 ml) for complex dental procedures. approximately 13% of these pediatric patients required additional injections of anesthetic for complete anesthesia. dosages in pediatric patients should be reduced, commensurate with age, body weight, and physical condition [see dosage and administration (2.2)]. in clinical trials, 54 patients between the ages of 65 and 75 years, and 11 patients 75 years and over received zorcaine containing epinephrine 1:100,000. among all patients between 65 and 75 years, doses from 0.43 mg/kg to 4.76 mg/kg (0.9 to 11.9 ml) were administered to 35 patients for simple procedures and doses from 1.05 mg/kg to 4.27 mg/kg (1.3 to 6.8 ml) were administered to 19 patients for complex procedures. among the 11 patients ≥ 75 years old, doses from 0.78 mg/kg to 4.76 mg/kg (1.3 to 11.9 ml) were administered to 7 patients for simple procedures and doses of 1.12 mg/kg to 2.17 mg/kg (1.3 to 5.1 ml) were administered to 4 patients for complex procedures. approximately 6% of patients between the ages of 65 and 75 years and none of the 11 patients 75 years of age or older required additional injections of anesthetic for complete anesthesia compared with 11% of patients between 17 and 65 years old who required additional injections. no overall differences in safety or effectiveness were observed between elderly subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. no studies have been performed with articaine hydrochloride 4% and epinephrine 1:200,000 injection or articaine hydrochloride 4% and epinephrine 1:100,000 injection in patients with renal or hepatic impairment [see warnings and precautions (5.2)].

UBISTESIN FORTE INJECTION Singapore - engelsk - HSA (Health Sciences Authority)

ubistesin forte injection

joyson pte. ltd. - articaine hcl; epinephrine hcl eqv epinephrine - injection - 40 mg/ml - articaine hcl 40 mg/ml; epinephrine hcl eqv epinephrine 0.01 mg/ml

Artinibsa 4% with Epinephrine 1:100000 72 MILLIGRAM/1.8 MILLILITER, 32.4 MICROGRAM/1.8 MILLILITER Jordan - engelsk - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

artinibsa 4% with epinephrine 1:100000 72 milligram/1.8 milliliter, 32.4 microgram/1.8 milliliter

مستودع أدوية برقان - burqan drug store - articaine hcl 72 milligram/1.8 milliliter, epinephrine bitartrate 32.4 microgram/1.8 milliliter - 72 milligram/1.8 milliliter, 32.4 microgram/1.8 milliliter

Artinibsa 4% with Epinephrine 1:200000 72 MG/1.8 ML, 16.2 MCG/1.8 ML Jordan - engelsk - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

artinibsa 4% with epinephrine 1:200000 72 mg/1.8 ml, 16.2 mcg/1.8 ml

مستودع أدوية برقان - burqan drug store - articaine hcl 72 mg/1.8 ml, epinephrine bitartrate 16.2 mcg/1.8 ml - 72 mg/1.8 ml, 16.2 mcg/1.8 ml

SEPTANEST SP SOLUTION Canada - engelsk - Health Canada

septanest sp solution

septodont - epinephrine (epinephrine bitartrate); articaine hydrochloride - solution - 0.01mg; 40mg - epinephrine (epinephrine bitartrate) 0.01mg; articaine hydrochloride 40mg - vasoconstrictors